Answers are grounded in this paper and cite their sources.
Innovative approach enhances immunotherapy efficacy in cancer, implying improved treatment outcomes.
Cytokine armoring of CAR T cells for enhancing the immunotherapy of cancer. Reprogramming of CAR T-cell phenotypes through (a) IL-15⁸ or (b) IL-9Rα⁹ engineering. Reprogramming of the tumor microenvironment and recruitment of host antitumor immunity through (c) IL-36γ¹⁰ or (d) IL-12¹¹,¹² engineering. (e) Tumor-inducible cytokine expression utilizing synthetic NFAT or endogenous NR4A2 promoter systems to restrict systemic expression of potent cytokines for improved safety.
No takes yet. Share an insight, caveat, or question.
Sek et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: